#Celltherapy
Love engineering T cells? 🧬

Winship Cellular Therapy Initiative at Emory is hiring an Associate Academic Research Scientist to help investigators build CAR, TCR, ADC & bispecific therapies for solid tumors.

Atlanta, on-site.
staff-emory.icims.com/jobs/175932/...
#CellTherapy
Careers | Emory University | Atlanta GA
staff-emory.icims.com
November 18, 2026 at 1:52 AM
Pfizer paid $330 million upfront and gained exclusive rights to three preclinical programs treating autoimmune diseases using in vivo cell therapy.

#CART #INVivo #CellTherapy
Pfizer pays Starna $330 million upfront
Source: BioPharma Dive
realfeedapp.com
November 18, 2026 at 6:00 PM
November 14, 2026 at 4:20 PM
A step forward in evolving cell therapies for AML: integrating TCR, CAR, BiTE, and safety switch into a single engineered T cell highlights how the field is moving toward multi-functional, adaptable designs to overcome tumor complexity.

vist.ly/5tbds

#Immunotherapy #AML #CellTherapy
T Cell Activation Pathway Diagram
AbstractBackground. Cancer immunotherapy with transgenic T-cell receptor-engineered T cells (TCR-T) enables the targeting of intracellular tumor-specific a
doi.org
November 18, 2026 at 12:00 PM
🧬 A review co-authored by @ericvivier.bsky.social explores engineering immune cells inside the body. Early trials in cancer and autoimmunity suggest feasibility.
#CellTherapy
Science Immunology · doi.org/10.1126/scii...
Programming immunity in situ: A new frontier of in vivo cell engineering
Developments and challenges of in vivo cell engineering for improved in situ therapies are reviewed.
doi.org
November 11, 2026 at 3:35 PM
🧬 Gene & Cell Therapy | #RareDiseases 🚀
#LucidQuest delivers sharp insights to help biotechs, investors & BD teams stay ahead in fast-moving markets.
📩 info@lqventures.com or http://dlvr.it/TWKgbB
#GeneTherapy #CellTherapy #Biotech #DueDiligence #InvestmentInsights
Gene & Cell Therapy and Rare Disease Intelligence - LucidQuest
Strategic insights for gene and cell therapy from R&D through commercialization. Primary KOL research, competitive analysis, and investment diligence in rare diseases.
dlvr.it
November 14, 2026 at 10:19 AM
Heading to #Cell2026? Join Saisei Ventures' Sven Kili and Sarah Domoney for discussions on investment in #celltherapy, #genetherapy and #ATMP platforms, including advances in manufacturing and emerging technologies. @biosurgerysven.bsky.social

View the full agenda here: bit.ly/4za23VE
November 10, 2026 at 5:24 PM
Roche acquiring Poseida Therapeutics for up to $1.5B tells you everything about the potential of off-the-shelf CAR-T therapy. A major milestone for a company we believe in.
poseida.com
#Biotech #CellTherapy #BluegrassAngels
Genentech: Poseida Therapeutics
Breakthrough science. One moment, one day, one person at a time.
poseida.com
November 10, 2026 at 4:56 PM
It was our pleasure at CET BET Divisions at IMCB, A*STAR, to host an education and sharing session with Singapore MediaCorp for the filming of their new drama "The Leftovers 幸存者". Starstruck and lots of fun! Now on Netflix.

#stemcells #celltherapy #imcb #astar #scss #mediacorp #TheLeftovers
November 9, 2026 at 1:51 PM
Lipid nanoparticles reprogrammed tumour-associated macrophages into CAR-M cells and promoted TREM2 degradation. With PD-1 blockade, the approach extended survival in mice🧬
#CellTherapy
Nature Materials · doi.org/10.1038/s415...
In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites - Nature Materials
Targeted lipid nanoparticles reprogram TREM2+-tumour-associated macrophages in ascitic fluid into chimeric antigen receptor macrophage cells, providing an in situ cell engineering strategy that alters...
doi.org
November 8, 2026 at 6:02 PM
An adapter protein can redirect CAR immune cells toward target cells by linking an antigen target to the CAR-binding domain. Arcellx’s patent grant covers multifunctional CAR compositions for modulating immune responses, including in cancer. #Arcellx #US12780932B1 #CellTherapy
November 7, 2026 at 1:51 PM
Local irradiation triggered TNF release from engineered CAR-T cells and improved tumour control in preclinical experiments. Human safety and benefit remain untested. 🧬
#CellTherapy
Nature Cancer · doi.org/10.1038/s430...
Spatiotemporal control of CAR-T cell TNF release via tumor-targeted irradiation - Nature Cancer
Masoumi et al. engineered CAR-T cells with a radiation-inducible promoter controlling the expression and local release of the cytokine TNF upon tumor irradiation.
doi.org
November 6, 2026 at 9:16 AM
A Frontiers in Aging perspective proposes encapsulated cells as a steady source of an antiaging protein, presenting the approach as a potential solution.

Link as first comment.

#longevity #geroscience #celltherapy #agingresearch #biotechnology
November 6, 2026 at 10:22 AM
🧬 Gene & Cell Therapy | #RareDiseases 🚀
#LucidQuest delivers sharp insights to help biotechs, investors & BD teams stay ahead in fast-moving markets.
📩 info@lqventures.com or http://dlvr.it/TWC6pd
#GeneTherapy #CellTherapy #Biotech #DueDiligence #InvestmentInsights
Gene & Cell Therapy and Rare Disease Intelligence - LucidQuest
Strategic insights for gene and cell therapy from R&D through commercialization. Primary KOL research, competitive analysis, and investment diligence in rare diseases.
dlvr.it
November 5, 2026 at 9:01 AM
Cell and Gene Therapy is transforming modern medicine through innovative treatments and advanced genetic technologies. Discover key industry trends and growth opportunities.

#CellTherapy #GeneTherapy #Healthcare
November 3, 2026 at 11:59 AM
The agency issued final guidance requiring manufacturers to implement a potency assurance strategy across the entire lifecycle of cell and gene therapy products to ensure batch consistency before patient delivery.

#CellTherapy #GeneTherapy #FDA
FDA issues new rules for cell therapy potency testing
Source: FDA
realfeedapp.com
November 3, 2026 at 7:20 AM
This month we're supporting three events covering a range of topics stem cells, cell therapy and animal-free human specific research.

#conferences #animalfree #humanspecific #stemcells #celltherapy
November 2, 2026 at 9:37 AM
Editing the RFX gene to reduce its protein expression is proposed to produce cells with altered immune recognition. Janssen Biotech’s patent application covers methods and materials for engineering such hypoimmunogenic cells. #JanssenBiotech #CellTherapy #US20260337579
November 2, 2026 at 6:09 AM
Allogeneic Dendritic Cells: Transforming the Impact of Cancer Immunotherapy

www.dl.begellhouse.com/journals/2ff...

#DendriticCells #CancerImmunotherapy #CellTherapy
October 30, 2026 at 7:00 PM
Machine learning models using longitudinal laboratory data predict survival in allogeneic stem cell recipients
doi.org/10.1177/0963...
#transplant #celltherapy #machinelearning #precisionmedicine
@journals.sagepub.com
October 29, 2026 at 3:30 AM
Immune cells engineered with multiple antigen receptors plus IL-15 could recognize more than one target for treating immune-related disorders. Patent application from University of Texas System #UTSystem: #US20260325440 #CellTherapy
October 29, 2026 at 7:32 PM
XellSmart’s off-the-shelf XS411 lifted motor scores in nine patients, and its 30-person Phase II trial has finished enrolling.

Link as first comment.

#longevity #geroscience #XellSmart #XS411 #celltherapy
October 28, 2026 at 12:25 PM
We're excited to be heading to Boston for @Advanced Therapies USA 2027!

More about the event > zurl.co/fIqFj

We looking forward to talking about our range of animal-free Cell Therapy Grade proteins > zurl.co/taYQo

#animalfree #celltherapy #genetherapy
October 27, 2026 at 8:18 AM
After two participant deaths in a Phase 2a trial for autoimmune diseases, Artiva Biotherapeutics has announced the end of its AlloNK natural killer cell therapy development and major staff cuts. One death was linked to fludarabine chemotherapy, while the cause o…

#CellTherapy #ClinicalTrial #Safety
Two trial participants died
Source: BioPharma Dive
realfeedapp.com
October 27, 2026 at 6:00 PM
Armoring #CARTcelltherapy with anti-inflammatory molecules offers new avenues for anti-fibrotic therapies in #ChronicKidneyDisease & other #Fibrosis conditions www.jci.org/articles/vie... @JonEpsteinLab #CellTherapy #CARTCell #TranslationalScience
www.jci.org
October 26, 2026 at 4:36 PM